A review and meta-analysis published in Diabetes Metabolism Research and Reviews has revealed that tirzepatide has a neutral effect on heart failure outcomes in people with type 2 diabetes or obesity. Across 11 randomized controlled trials involving 13,378 participants, tirzepatide showed no significant difference in heart failure risk compared with placebo or other glucose-lowering medications. Yi-Meng He and colleagues conducted the study.

This study's background indicates that, at the time, evidence for the cardioprotective effect of tirzepatide was inconsistent; thus, further investigation was necessary to determine whether this dual GIP/GLP-1 receptor agonist would affect heart failure outcomes. The investigators also included the conclusions in the introduction to note that tirzep

See Full Page